Optimization of the tactics of adjuvant chemotherapy in patients with colon cancer taking into account clinical and morphological characteristics
- Authors: Ivanova A.K1, Orlova R.V1,2,3, Raskin G.A4, Kutukova S.I1,5
-
Affiliations:
- City Clinical Oncological Dispensary
- Saint Petersburg State University
- Clinical Hospital № 122
- Russian Scientific Center for Radiology and Surgical Technologies n.a. Acad. A.M. Granov
- Pavlov University
- Issue: Vol 28, No 7 (2021)
- Pages: 87-94
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313184
- DOI: https://doi.org/10.18565/pharmateca.2021.7.87-94
- ID: 313184
Cite item
Abstract
Background. Colorectal cancer (CRC) remains an urgent problem in modern oncology. With the introduction of CRC screening, early stages of disease are more often detected and, accordingly, adjuvant chemotherapy is prescribed. Before the appointment of adjuvant chemotherapy, the known factors of a negative prognosis are taken into account - a low degree of cell differentiation, the presence of lymphovascular/perineural invasion, R+, surgery in conditions of intestinal obstruction/peritonitis, surgery with an inadequate volume of lymphadenectomy (less than 12 lymph nodes studied, CEA>2.35 ng/ml after surgery), but none of these factors are universal. At the moment, it is interesting to study new prognostic factors and their influence on relapse-free survival in patients with CRC. Objective. Optimization of adjuvant chemotherapy and an increase in relapse-free survival in patients with CRC by analyzing their clinical and morphological characteristics. Methods. The study included 113 patients: 53 with stage II colon cancer (group A) and 60 with stage III colon cancer (group B). The median follow-up was 60 months. From the start of follow-up, distant metastases were revealed in patients at various times, as a result of which all patients in groups A and B were divided into subgroups. In patients of subgroup 1 of each group, no distant metastases were recorded for 60 months using standard observational methods; in patients of subgroup 2, the progression of the process in the form of the appearance of distant metastases was recorded. Further, the clinical characteristics of the patient (gender, age, tumor localization, the nature of the surgical treatment performed) and the morphological characteristics of the tumor were assessed, for which all histological blocks of patients were additionally examined for the CXCR4chemokine receptor expression, CCR10, Ki-67 proliferation index, and KRAS mutation. Results. The median relapse-free period is significantly lower in the subgroups of patients with distant metastases (subgroup 2), where additional factors of negative prognosis were revealed - high CXCR4 chemokine receptor expression in tumor tissue and low Ki-67 proliferation index. Conclusion. Assessment of the combination of clinical and morphological characteristics of patients with CRC will help us to optimize adjuvant treatment.
Full Text
About the authors
A. K Ivanova
City Clinical Oncological Dispensary
Email: oncolog.ivanova@yandex.ru
St. Petersburg, Russia
R. V Orlova
City Clinical Oncological Dispensary; Saint Petersburg State University; Clinical Hospital № 122St. Petersburg, Russia
G. A Raskin
Russian Scientific Center for Radiology and Surgical Technologies n.a. Acad. A.M. GranovSt. Petersburg, Russia
S. I Kutukova
City Clinical Oncological Dispensary; Pavlov UniversitySt. Petersburg, Russia
References
- Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2019 году. М., 2020. С. 16-23.
- Практические рекомендации по лечению злокачественных опухолей Российского общества клинической онкологии, версия 2020 г. М., 2020. С. 366-68.
- Gerdes J., Schwab U., Lemke H., Stein H. Producing of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20. doi: 10.1002/ijc.2910310104.
- Conlin A., Smith G., Carey F.A., et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283-86. doi: 10.1136/gut.2005.066514.
- Tie J., Lipton L., Desai J., et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17(5):1122-30. doi: 10.1158/1078-0432.CCR-10-1720.
- Hanahan D., Weinberg R. The hall marks of cancer: the next generation. Cell. 2011;144:646-74. doi: 10.1016/.cell.2011.02.013.
- Чердынцева Н.В., Гервас П.А., Литвяков Н.В. и др. Хемокины и прогрессия злокачественных новообразований. Медицинская иммунология. 2006;8(2-3):355-56
- Симбирцев А.С. Цитокины: классификация и биологические функции. Цитокины и воспаление. 2004;3(2):16-22
- Rivera C.G., Bader J.S., Popel A.S. Angiogenesis-associated crosstalk between collagens, CXC chemokines, and thrombospondin domain-containing proteins. Ann Biomed Eng. 2011;39(8):2213-22. doi: 10.1007/s10439-011-0325-2.
- Бережная Н.М., Чехун В.Ф. Иммунология злокачественного роста. Киев, 2005. 791 с.
- Cancer Research UK. Bowel cancer. Cancer Statistics Key Facts. 2014.
- Орлова А.К., Иванова Г.А. Раскин С.И. и др. Экспрессия хемокинового рецептора CXCR4 в опухолевой ткани как дополнительный фактор прогноза больных раком ободочной кишки. Фарматека. 2019;12:44-9.